tetano
Editor, Senior Moderator
Cytokine
. 2021 Jun 7;155618.
doi: 10.1016/j.cyto.2021.155618. Online ahead of print.
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
Takehiro Hasegawa[SUP] 1 [/SUP], Atsushi Nakagawa[SUP] 2 [/SUP], Kohjin Suzuki[SUP] 3 [/SUP], Kazuto Yamashita[SUP] 4 [/SUP], Saya Yamashita[SUP] 5 [/SUP], Niina Iwanaga[SUP] 4 [/SUP], Eiya Tamada[SUP] 4 [/SUP], Kenta Noda[SUP] 4 [/SUP], Keisuke Tomii[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is an acute respiratory disease; approximately 5% of patients developing severe COVID-19. It is known that cytokine release is associated with disease severity, but the relationship between the different clinical phenotypes and inflammatory endotypes is not well understood.
Objective: This study investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes.
Methods: Interleukin (IL) -6, C-reactive protein (CRP), C-X-C motif chemokine (CXCL) 9, IL-18, C-C motif chemokine (CCL) 3, CCL17, IL-10, and vascular endothelial growth factor (VEGF) were measured in 57 COVID-19 patients, and their association with clinical characteristics was examined using a cluster analysis.
Results: Significantly higher blood levels of the eight inflammatory markers were noted in patients who developed acute respiratory distress syndrome (ARDS) than in those who did not develop ARDS (non-ARDS). Using a cluster analysis, the patient groups were classified into four clusters, of which two had patients with high IL-6 and CRP levels. In the cluster with high levels of Type 1 (T1) inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS, 65% of the patients developed acute kidney injury (AKI), and 78% of the patients developed pulmonary fibrosis.
Conclusions: In the cluster with high levels of T1 inflammatory markers, the patients frequently suffered from tissue damage, manifested as ARDS and AKI. Our findings identified distinct T1 inflammatory endotypes of COVID-19 and suggest the importance of controlling inflammation by monitoring T1 biomarkers and treating accordingly to limit the severity of the disease.
Keywords: AKI; ARDS; COVID-19; Cytokine storm; Endotype; Fibrosis.
. 2021 Jun 7;155618.
doi: 10.1016/j.cyto.2021.155618. Online ahead of print.
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
Takehiro Hasegawa[SUP] 1 [/SUP], Atsushi Nakagawa[SUP] 2 [/SUP], Kohjin Suzuki[SUP] 3 [/SUP], Kazuto Yamashita[SUP] 4 [/SUP], Saya Yamashita[SUP] 5 [/SUP], Niina Iwanaga[SUP] 4 [/SUP], Eiya Tamada[SUP] 4 [/SUP], Kenta Noda[SUP] 4 [/SUP], Keisuke Tomii[SUP] 2 [/SUP]
Affiliations
- PMID: 34127355
- DOI: 10.1016/j.cyto.2021.155618
Abstract
Background: Coronavirus disease 2019 (COVID-19) is an acute respiratory disease; approximately 5% of patients developing severe COVID-19. It is known that cytokine release is associated with disease severity, but the relationship between the different clinical phenotypes and inflammatory endotypes is not well understood.
Objective: This study investigated the association between inflammatory biomarker-based endotypes and severe COVID-19 phenotypes.
Methods: Interleukin (IL) -6, C-reactive protein (CRP), C-X-C motif chemokine (CXCL) 9, IL-18, C-C motif chemokine (CCL) 3, CCL17, IL-10, and vascular endothelial growth factor (VEGF) were measured in 57 COVID-19 patients, and their association with clinical characteristics was examined using a cluster analysis.
Results: Significantly higher blood levels of the eight inflammatory markers were noted in patients who developed acute respiratory distress syndrome (ARDS) than in those who did not develop ARDS (non-ARDS). Using a cluster analysis, the patient groups were classified into four clusters, of which two had patients with high IL-6 and CRP levels. In the cluster with high levels of Type 1 (T1) inflammatory markers such as CXCL9 and IL-18, 85% of the patients had ARDS, 65% of the patients developed acute kidney injury (AKI), and 78% of the patients developed pulmonary fibrosis.
Conclusions: In the cluster with high levels of T1 inflammatory markers, the patients frequently suffered from tissue damage, manifested as ARDS and AKI. Our findings identified distinct T1 inflammatory endotypes of COVID-19 and suggest the importance of controlling inflammation by monitoring T1 biomarkers and treating accordingly to limit the severity of the disease.
Keywords: AKI; ARDS; COVID-19; Cytokine storm; Endotype; Fibrosis.